Akero Therapeutics, Inc. (AKRO) announced a statistically significant histological improvement in the primary endpoint of its mid-stage study, evaluating the efficacy and safety of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3, at week 96. EFX, the company’s lead product candidate, is being developed for a serious liver disease caused by metabolic dysregulation that does not have any approved therapies. We remind the investor ...